Probity Advisors Inc. grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 9.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,742 shares of the company’s stock after buying an additional 403 shares during the quarter. Probity Advisors Inc.’s holdings in Zoetis were worth $477,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc grew its position in shares of Zoetis by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after acquiring an additional 293,614 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Zoetis by 9,042.7% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after acquiring an additional 14,178,765 shares during the period. Polen Capital Management LLC grew its position in shares of Zoetis by 1.9% during the 4th quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock valued at $817,212,000 after acquiring an additional 178,893 shares during the period. FMR LLC lifted its stake in shares of Zoetis by 209.7% during the 4th quarter. FMR LLC now owns 7,245,748 shares of the company’s stock valued at $619,801,000 after buying an additional 4,905,887 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Zoetis by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after buying an additional 785,088 shares in the last quarter. 90.78% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis stock traded up $0.56 during trading hours on Wednesday, reaching $102.94. The stock had a trading volume of 1,059,100 shares, compared to its average volume of 2,221,209. The firm has a market cap of $48.81 billion, a PE ratio of 32.89, a price-to-earnings-growth ratio of 2.55 and a beta of 0.91. Zoetis Inc has a 52 week low of $78.90 and a 52 week high of $103.97. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the firm earned $0.75 EPS. The company’s revenue was up 6.5% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc will post 3.48 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be given a $0.164 dividend. The ex-dividend date is Thursday, July 18th. This represents a $0.66 annualized dividend and a dividend yield of 0.64%. Zoetis’s dividend payout ratio is 21.09%.
A number of analysts recently commented on the stock. Gabelli cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target on the stock. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a research note on Friday, April 19th. UBS Group assumed coverage on shares of Zoetis in a research note on Wednesday, March 20th. They issued a “neutral” rating on the stock. BMO Capital Markets increased their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research note on Monday, February 25th. Finally, SunTrust Banks assumed coverage on shares of Zoetis in a research note on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $103.15.
In other news, CEO Juan Ramon Alaix sold 312,109 shares of Zoetis stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total value of $29,356,972.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Glenn David sold 8,191 shares of Zoetis stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $102.22, for a total transaction of $837,284.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 447,975 shares of company stock valued at $42,728,902. Corporate insiders own 0.29% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: P/E Growth (PEG)
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.